What Dental Practices Sell For in 2026

Updated August 2026 · refreshed quarterly. Next scheduled review: November 2026.

The dental practice M&A market in 2026 is highly active but increasingly stratified. Following the rapid consolidation of the past decade and the subsequent interest rate correction, corporate buyers and private equity platforms have returned to the market with renewed focus, but their underwriting standards have tightened considerably. In the United Kingdom, Christie & Co reported advising on or selling 1,241 practices with a combined value of £1.68 billion in 2025, while completing 432 formal RICS valuations worth a combined £360 million. In the United States, the DSO (Dental Support Organization) model continues its relentless expansion, with platforms like Heartland Dental surpassing 1,900 offices and PDS Health crossing the 1,000-office mark across 24 states (Becker's Dental).

For a professionally represented, multi-surgery dental practice group generating over £1M in defended EBITDA, valuations typically command a premium multiple of 8.0x to 11.0x EBITDA in both markets. However, the dental sector is unique in its valuation conventions. In the UK, the market still heavily references goodwill as a percentage of gross fee income, with NASDAL reporting overall goodwill at 119% of gross fees in Q1 2026 and the Dental Elite Goodwill Report 2026 recording the highest average transaction price in a decade at £1,383,637. Understanding how to reconcile this traditional goodwill percentage with the EBITDA multiple that a corporate acquirer will actually pay, particularly after adjusting for principal clinical hours, is the single most important step in preparing a dental practice for sale.

Contents

1. Why Two Businesses with the Same EBITDA Sell for Very Different Multiples
2. The 2026 EBITDA Multiples Ladder
3. How These Businesses Are Actually Valued
4. The NHS Contract: Transfer Mechanics and Their Impact on Value
5. What Kills the Multiple
6. Worked Examples: Goodwill vs EBITDA
7. 2025 and 2026 Transactions: United Kingdom
8. 2025 and 2026 Transactions: United States
9. The Buyer Universe: Who is Acquiring in 2026
10. Demand Drivers and Regulatory Calendar
11. Deal Structure: How the Consideration is Paid
12. Public Company Multiples
13. FAQ
14. Glossary
15. Methodology and Sources

Why Two Businesses with the Same EBITDA Sell for Very Different Multiples

In the lower mid-market, an EBITDA multiple is not a fixed commodity price. It is a quality score. A buyer evaluates the risk of those earnings continuing after the founder departs, the cost of integrating the practice into their existing infrastructure, and the growth potential of the patient base and catchment area. The framework below details the thirty factors that separate a practice commanding a 9.0x multiple from one struggling to achieve 5.0x. Every factor is anchored to the specific economics of dentistry, not generic M&A theory.

Dimension A: Financial (22% weighting)

Dimension B: Deal Process & Buyer Access (22% weighting)

The single cheapest dimension to move, because it requires no internal business change, only the right representation across healthcare M&A.

Dimension C: Customer & Revenue (16% weighting)

Dimension D: Operations (14% weighting)

Dimension E: People & Organisation (13% weighting)

Dimension F: Strategic (13% weighting)

The 2026 EBITDA Multiples Ladder

The ranges below are derived from the NASDAL Goodwill Survey (Tier 1), the Dental Elite Goodwill Report 2026 (Tier 1), Christie & Co market data (Tier 1), and DealFlowAgent's own advisory experience (labelled as such). The lower bound of each band represents an unprepared business sold without competitive tension. The upper bound represents a prepared business, professionally represented, in a competed process.

£250K to £500K Defended EBITDA

£500K to £1M Defended EBITDA

£1M to £2M Defended EBITDA

£2M to £3M Defended EBITDA

£3M to £5M Defended EBITDA

£5M to £10M Defended EBITDA

£10M+ Defended EBITDA

Footnote: Businesses generating under £250,000 in adjusted profit are typically valued on a Seller's Discretionary Earnings (SDE) basis rather than an EBITDA multiple, generally attracting 2.0x to 3.5x SDE. The Dental Elite Goodwill Report 2026 records the average independent buyer multiple at 3.44x, which aligns with this SDE-priced segment. Indicative revenue bands are not provided, as dental practice margins vary significantly based on the principal's clinical contribution and the NHS/private mix.

Calculate your indicative valuation

How These Businesses Are Actually Valued

The dental sector is unique in its valuation conventions. While the broader M&A market speaks exclusively in EBITDA multiples, the UK dental market still heavily references goodwill as a percentage of gross fee income. This creates confusion for owners who encounter both metrics and cannot reconcile them. This section explains both methodologies and demonstrates how they relate to one another.

The Goodwill Percentage Convention

The NASDAL Goodwill Survey is the longest-running dataset in UK dental M&A, published quarterly since 2008. It reports the price paid for dental practices as a percentage of the practice's annual gross fee income. For the quarter ending 31 October 2025, NASDAL reported overall goodwill at 119% of gross fees. Mixed practices commanded a premium at 144%, while purely NHS practices dropped to 111% and private practices sat at 100%.

The Dental Elite Goodwill Report 2026 provides a complementary dataset. It reports the average completed transaction price at £1,383,637 (the highest in a decade, representing a 7.5% increase on the prior year), with group buyers paying an average of £2,500,709 and independent buyers paying £886,562.

The EBITDA Multiple Convention

Corporate acquirers and private equity firms do not buy revenue; they buy cash flow. They underwrite deals based on Adjusted EBITDA, which is the practice's profit after normalising for the principal's clinical contribution, personal expenses, and one-off items. The Dental Elite Goodwill Report 2026 records the average group buyer multiple at 7.15x EBITDA, with Tier 2 buyers (groups of 20+ practices) paying up to 7.78x.

Reconciling the Two: The Critical Arithmetic

The relationship between goodwill percentage and EBITDA multiple is determined by the practice's adjusted EBITDA margin. A practice with a 30% adjusted margin selling at 120% of gross fees is achieving a 4.0x EBITDA multiple (120% divided by 30%). A practice with a 20% margin selling at the same 120% is achieving a 6.0x multiple (120% divided by 20%). This reconciliation is the most useful analytical tool on this page, because it allows an owner to translate between the two conventions at their own margin level.

The Principal-Hours Normalisation

The single largest adjustment in a dental practice valuation is normalising the principal's clinical hours. If a principal generates £400,000 in gross fees and takes it all as profit, that £400,000 is not EBITDA. A buyer must replace that clinical output with an associate at market rates. If the prevailing associate split is 45%, the buyer incurs £180,000 in replacement costs, reducing the true EBITDA by that amount. DealFlowAgent data indicates that associate-led EBITDA margins typically range from 25% to 40%, depending on the private/NHS mix and operational efficiency.

This normalisation is why the NASDAL goodwill percentage and the EBITDA multiple can appear to tell different stories. A principal-dependent practice may sell at a high goodwill percentage (because the gross fees are large relative to the price), but a low EBITDA multiple (because the adjusted profit after principal replacement is small).

Recurring Revenue: The Plan Premium

In dentistry, recurring revenue takes the form of capitation plans (e.g., Denplan, Practice Plan, DPAS). Buyers place a significant premium on this income because it provides predictable monthly cash flow, reduces reliance on volatile high-ticket cosmetic treatments, and heavily drives patient retention. A practice with 40% of its revenue derived from stable plan memberships will consistently command a higher multiple than a purely fee-per-item practice with identical EBITDA, because the earnings quality is demonstrably superior.

The NHS Contract: Transfer Mechanics and Their Impact on Value

This section addresses the single most common source of deal delay, complexity, and value destruction in UK dental M&A. An NHS General Dental Services (GDS) contract cannot be sold or assigned outright. It is a personal contract between the contractor (the practice owner or partnership) and the NHS commissioner (the Integrated Care Board, formerly the Local Area Team). Understanding the transfer mechanics is essential for any owner considering a sale.

Route 1: The Partnership Route

The traditional method for transferring an NHS contract from a sole practitioner involves the following steps. First, the seller incorporates a partnership with the buyer (or the buyer's nominee). Second, the partnership applies to the commissioner to be added to the contract. Third, after a period of joint operation (typically 3 to 6 months), the original partner retires from the partnership, leaving the buyer as the sole contractor. This route preserves the contract without requiring a new application, but it introduces significant timeline risk. If the commissioner is slow to process the application, or if the buyer's clinical credentials are questioned, the deal can stall for months.

Route 2: The Share Sale

Where the practice is already incorporated (i.e., the NHS contract is held by a limited company), a share sale is the cleaner route. The buyer acquires the shares of the company, and the contract remains within the same legal entity. However, this requires change-of-control consent from the commissioner, which is not automatic. The commissioner will assess the new owners' suitability, clinical governance arrangements, and financial standing. This route is faster than the partnership route but carries the risk that consent is withheld or conditional.

The Valuation Impact

Practices that have not prepared for contract transfer face a direct valuation penalty. A sole-trader structure requiring the partnership route adds 3 to 6 months to the deal timeline, increases legal costs, and introduces the risk of the buyer walking away during the extended transition period. Corporates will either discount the price to reflect this risk or, increasingly, simply decline to make an offer on poorly structured practices. The single most valuable preparatory step for any NHS practice owner planning a sale within 24 months is to incorporate the practice and hold the contract within a limited company, removing the partnership route requirement entirely.

Scotland, Wales, and Northern Ireland

The NHS dental contract regimes in Scotland, Wales, and Northern Ireland differ materially from the English GDS system described above. Wales implemented a new NHS dental contract from 1 April 2026, the first major reform in over 20 years. Scotland operates under a different commissioning structure through NHS boards. This guide's contract transfer analysis applies specifically to England. Owners in the devolved nations should seek specialist legal advice on their specific regime.

What Kills the Multiple

Corporate development directors look for reasons to say no. In the dental sector, these six issues reliably destroy enterprise value during diligence. Each is written from the buyer's perspective, because that is the voice that determines the price.

1. "The principal is the practice." If the exiting owner generates 70% of the clinical revenue and holds all the key patient relationships, the business has no transferable goodwill. We are buying a job, not an asset, and the multiple will reflect that extreme key person risk. We will apply a replacement cost that reduces the EBITDA to a fraction of what the seller's accountant presented, and we will apply a discount multiple to that reduced figure.

2. "The NHS contract is chronically underperforming." A history of missing UDA targets and suffering clawbacks tells us two things: the practice cannot attract or retain associates willing to deliver NHS care, and the revenue base is insecure. Clawback is not a one-off event; it is a structural indicator of operational failure. We will discount the valuation heavily, and in some cases we will simply walk away rather than inherit the problem.

3. "The associates are on a hair-trigger." If the associates have no well-drafted contracts, no restrictive covenants, or are threatening to leave if the practice is sold, the revenue is entirely unprotected. Patient loyalty in dentistry follows the clinician, not the brand. If the associates leave, the patients leave with them. We will not pay a premium multiple for a flight-risk clinical team.

4. "The premises are a liability." A short lease (under 10 years) with no right of renewal, or a freehold that requires massive capital expenditure to meet HTM 01-05 decontamination standards, represents immediate risk and cost. We will deduct that capex directly from the purchase price, pound for pound. A practice requiring £200,000 of equipment upgrades is worth £200,000 less than an identical practice that is fully compliant.

5. "The NHS contract transfer is a mess." Because a GDS contract cannot be sold outright, a poorly structured sole-trader practice requires a complex partnership route or incorporation process to transfer the contract. If the seller has not prepared this, the deal timeline extends by months, deal fatigue sets in, and offers drop. We have seen deals collapse entirely because the seller did not understand this mechanic until month six of the process.

6. "The numbers are fiction." Presenting 'adjusted EBITDA' that adds back legitimate business expenses, or failing to properly deduct the market-rate cost of the principal's clinical hours, destroys trust immediately. If the seller's broker does not understand dental normalisation, we assume the rest of the data room is equally flawed. We will either walk away or recut the numbers ourselves and offer on our figure, which will be materially lower.

Worked Examples: Goodwill vs EBITDA

To illustrate how the market convention (goodwill percentage) reconciles with the corporate underwriting standard (EBITDA multiple), consider two illustrative practices. Both generate £1,000,000 in gross fee income, but their operational structures yield vastly different valuations.

Practice A: The Discount Profile (Principal-Dependent, Mixed NHS/Private)

Practice B: The Premium Profile (Associate-Led, Strong Plan Income)

These examples are illustrative constructions to demonstrate the mathematics of principal replacement. They are not market data.

The difference is stark: the same gross fee income produces enterprise values ranging from £900,000 to £2,287,500, a gap of £1.4 million driven entirely by operational structure and process quality. Practice B commands a higher multiple (7.5x vs 5.0x) applied to a higher EBITDA base (£305,000 vs £180,000), creating a compounding effect that rewards preparation.

2025 and 2026 Transactions: United Kingdom

Individual deal values in the dental sector are almost never disclosed. Unlike building services or fire safety M&A, where trade press occasionally reports consideration, dental practice sales are private transactions between a corporate and an owner-operator. Neither party publishes the price. The table below tracks confirmed corporate and group acquisition activity with consideration marked undisclosed where it is undisclosed. This is the honest position, and it is more useful than a fabricated figure.

What this table says when read together. The UK market is highly active but heavily bifurcated. While mega-deals like Bridgepoint's circa £800 million acquisition of mydentist dominate the headlines, the day-to-day market is driven by independent operators and emerging regional groups acquiring high-quality, multi-surgery clinics. Christie & Co reports that in Q1 2026 alone, they advised on, agreed, or sold 165 practices with a combined value of £167 million. Corporate buyers represent only 7% of completed transactions, but approximately 20% of the live pipeline is expected to complete into corporate ownership. The emergence of DeNovo's shared-ownership model represents a new structural option for principals who want liquidity without full exit.

Are you actively acquiring dental practices in the UK or US? Register your investment criteria with DealFlowAgent to receive off-market opportunities matching your mandate.

Book a confidential valuation call with DealFlowAgent

2025 and 2026 Transactions: United States

The US DSO market operates at a staggering scale, but like the UK, individual practice transaction values are strictly confidential. In the June 2026 Group Dentistry Now acquisition roundup, every operating-company acquisition was recorded as undisclosed. That is the norm, not an outlier.

What this table says when read together. The US market is characterised by relentless, programmatic M&A driven by private equity-backed DSOs. Platforms like MB2 and Heartland execute multiple partnerships monthly. The emergence of specialty DSOs (like Beacon Oral Specialists, now supporting 130+ oral surgeons across 106 locations) indicates a maturing market where buyers are willing to pay premiums for high-margin, specialised clinical models. The "partnership" terminology used by MB2 and Imagen reflects the joint venture structure common in US dental M&A, where the selling dentist retains equity in the local entity and participates in the platform's eventual recapitalisation.

The Buyer Universe: Who is Acquiring in 2026

United Kingdom

United States DSOs

Note: The corporate market consolidates rapidly. Inclusion on this list indicates verified recent activity, but acquisition appetite fluctuates based on funding cycles, integration capacity, and regulatory developments. A page that lists a dormant acquirer as active is worse than a shorter list.

Match with active buyers for your practice

Demand Drivers and Regulatory Calendar

The regulatory environment dictates practice operations, deal structures, and ultimately valuations. The UK dental market is experiencing a period of significant regulatory change, with three major developments occurring within a 12-month window.

The CMA Private Dentistry Market Study (March 2026 to March 2027)

The Competition and Markets Authority launched a 12-month market study into private dentistry on 5 March 2026, examining an £8.4 billion market. The BDA reported that interim findings confirm the market is "competitive and well-functioning," with an 8% real-terms reduction in private fees (practices absorbing cost increases rather than passing them to patients). Christie & Co's analysis confirms that the study has not dampened buyer appetite: offer volumes in H1 2026 are in line with H1 2025, while aggregate offer value is up approximately 43%. However, deal execution timelines have extended from 7.6 months to 8.8 months as buyers demand greater transparency and tighter warranties.

NHS UDA Reform (April 2026)

NHS England implemented significant contract changes from 1 April 2026, the first material reform to the UDA system since its introduction in 2006. Key changes include a mandate that 8.2% of contract value be directed to unscheduled care (11 Courses of Treatment per £10,000 of contract value), a new £75 payment structure for urgent access, rebanding of fissure sealants from Band 1 to Band 2 (increasing from 1 UDA to 3-5 UDAs), and an optional quality improvement programme worth £3,400 per practice per year. These changes alter the margin structure of NHS delivery and create both opportunities and risks for practices depending on their current service mix.

GDC Scope of Practice (November 2025)

The General Dental Council's revised Scope of Practice guidance, effective 1 November 2025, moved from fixed task lists to competency-based role descriptions. Dental hygienists and therapists can now carry out a wider range of treatments if trained, competent, and indemnified. This fundamentally improves practice skill-mix efficiency and allows practices to deliver more care through lower-cost clinicians, directly improving EBITDA margins for practices that adapt their clinical model accordingly.

Additional UK Regulatory Factors

United States Regulatory Factors

The US regulatory landscape is fundamentally different. There is no federal dental licensing regime; each of the 50 states operates its own dental board with distinct rules on scope of practice, supervision requirements, and corporate ownership. The corporate practice of dentistry doctrine, which in most states prevents non-dentist ownership of a clinical practice, is the structural fact that explains why US dental M&A operates through the DSO model. A DSO cannot own the clinical entity (the Professional Corporation); it provides management services under an MSA. This structure has specific implications for deal mechanics, tax treatment, and post-acquisition governance that vary by state.

Deal Structure: How the Consideration is Paid

Corporate buyers rarely write a single cheque for 100% of the enterprise value on completion day. Risk is shared between buyer and seller through structured consideration.

United Kingdom vs United States Comparison

Three Implications for Sellers

First, the headline multiple is not the cash-in-hand figure. A 7.0x multiple with a 25% earn-out means the guaranteed day-one payment is 5.25x, and the remaining 1.75x depends on hitting targets that the seller no longer controls. Second, equity rollover can be highly valuable if the platform executes its buy-and-build strategy successfully, but it is illiquid and carries execution risk. Third, the working capital adjustment is the most common source of post-completion disputes in dental M&A; sellers should model it carefully with their accountant before signing heads of terms.

Public Company Multiples

Public company multiples reflect global investor sentiment, liquidity premiums, and massive scale. There is no direct read-across from these figures to the valuation of a private, lower mid-market dental practice. Data retrieved August 2026.

Pure-play listed dental operators are exceptionally rare, as the sector is dominated by private equity. The major UK corporates (mydentist, PortmanDentex, Rodericks) are all privately held. In the US, no major DSO is publicly listed. The closest public comparables are dental supply and distribution companies, which operate fundamentally different business models.

The true valuation benchmark for clinical dental practices remains the private market data published by NASDAL, Dental Elite, and Christie & Co, supplemented by the transactional experience of specialist advisers.

For owners 12 to 36 months from a sale event, we build a detailed valuation and business optimisation report that typically identifies six to seven figures of additional enterprise value. Available standalone, or included as part of our sell-side advisory engagement for businesses planning a sale within 12 months. Book a confidential call to discuss your practice.

FAQ

What is the average EBITDA multiple for a dental practice in 2026?

For a prepared, associate-led practice generating £500K to £1M in defended EBITDA, the multiple typically ranges from 5.0x to 7.5x. Larger groups generating £1M to £2M command 7.0x to 9.0x. The Dental Elite Goodwill Report 2026 records the average group buyer multiple at 7.15x.

How does goodwill percentage compare to EBITDA multiples?

Goodwill is calculated as a percentage of gross fee income (e.g., 119% overall in Q1 2026 per NASDAL). EBITDA multiples apply to the adjusted profit. The relationship depends on the practice's adjusted margin: a practice with a 25% margin selling at 120% of fees achieves a 4.8x EBITDA multiple. A practice with a 20% margin at the same goodwill percentage achieves 6.0x.

Does a CQC rating affect my dental practice valuation?

No. The CQC does not issue ratings to dental practices. Unlike hospitals and care homes, dental practices are registered but not rated. What matters for valuation purposes is a clean registration status and a smooth transition of the Registered Manager, which is a completion mechanic rather than a value driver.

How do my clinical hours affect the valuation?

Buyers will deduct the cost of replacing your clinical hours (typically at a 45% to 50% associate split) from your reported profit to calculate the true Adjusted EBITDA. A principal working 4 clinical days per week and generating £500,000 in fees creates a replacement cost of £225,000 to £250,000. This is the single largest normalisation adjustment in dental valuation.

Can I sell my NHS dental contract?

No. An NHS General Dental Services (GDS) contract cannot be sold or assigned outright. It must be transferred either by incorporating the practice and executing a share sale (requiring change-of-control consent from the Integrated Care Board) or via the partnership route, where the buyer is added to the contract before the seller retires. Both routes have specific timelines and risks.

What multiple do US DSOs pay for dental practices?

US DSO multiples vary significantly by scale. Single-location practices typically attract 5.0x to 7.5x as add-on acquisitions. Multi-location groups with $1M to $3M EBITDA command 7.0x to 9.0x. Platform-grade groups with $5M+ EBITDA and full management infrastructure can achieve 10.0x to 12.0x or higher.

How long does it take to sell a dental practice?

Christie & Co data indicates the average time from offer accepted to completion is now trending toward 8.8 months, up from 7.6 months previously. The extension reflects increased diligence requirements and more internal approval layers from corporate buyers. NHS practices requiring the partnership route for contract transfer may take 12 months or longer.

Glossary

Methodology and Sources

This guide is built on primary filings, named institutional research with stated methodologies, and DealFlowAgent's proprietary advisory experience (labelled as such where it appears). Due to the strict confidentiality of individual dental practice transactions, we do not publish fabricated or estimated deal values. This is an honest position, not a gap. The dental sector has the weakest deal-value disclosure of any trade we cover, and publishing the gap is more credible than papering over it.

Our valuation ranges are triangulated from the following Tier 1 sources:

Where two sources conflict, both figures are presented with the methodological difference stated. Where DealFlowAgent's own view appears, it is labelled "DealFlowAgent data" or "DealFlowAgent estimate" in the same sentence.

Note: The regulatory and NHS contract frameworks discussed in this guide apply specifically to England. Scotland, Wales, and Northern Ireland operate under different NHS dental contract regimes. Wales implemented a new contract from April 2026. Owners in the devolved nations should seek specialist legal advice on their specific regime.

Related Valuation Guides

About DealFlowAgent

DealFlowAgent is a specialist sell-side M&A advisory firm representing owner-led businesses across the UK and US. We maintain an active, pre-qualified network of corporate acquirers, private equity sponsors, and independent groups seeking high-quality assets in healthcare, building services, and facilities management. Our dental practice expertise covers NHS contract transfer mechanics, principal-hour normalisation, and the specific diligence requirements of corporate dental acquirers.

If you advise owners in this trade, whether as an accountant, solicitor, or financial planner, we operate a structured professional referral programme that allows you to remain the trusted adviser while we handle the M&A workstream. Learn more about our adviser network.

To understand how we prepare businesses for a liquidity event, read about our exit readiness methodology or view our current buy-side mandates. For owners ready to explore their options, book a confidential call.

• Calculate your valuation
• Match with buyers
• Book a confidential call

Disclaimer

This guide is for informational purposes only and does not constitute financial, legal, or tax advice. Valuations are indicative and based on market data available at the time of publication. Individual practice valuations depend on specific circumstances. Seek independent professional advice before making any transaction decisions.

Your Advisory Team

Experienced Dealmakers Lead Your Exit

A senior M&A bench, plus a sector specialist recruited for your industry on every deal.

Announcing Soon

Head of M&A

Recently joined, name announcing soon

Recently joined from one of the largest M&A advisory firms in the UK. As an ex-Director, our new Head of M&A was selected from over 220 applicants to lead the advisory bench across Building Services and Healthcare.

Martin Watson

Senior Building Services & FM Advisor

Martin is one of the most well-connected figures in UK fire, security, building services and FM. He is Chairman of both the Fire Industry Association and the British Security Industry Association, the only person in the UK to hold both roles simultaneously. Martin spent over a decade in senior leadership at Mitie, latterly as Industry Liaison Director for its fire and security division, helping scale the business past £500m in revenue and playing a role in the £366m acquisition of Marlowe plc, which created one of the UK's largest compliance, fire and security services groups. He joined DealFlowAgent because owners in these sectors deserve a genuine sector-specialist advisor across valuation, business optimisation and buyer access. In recognition of his industry roles, he acts in a personal, non-partisan capacity.

James Duboullay

Senior M&A Advisor

• •25+ years across investment banking, M&A and fundraising
• •Sector focus: essential services and software
• •Long-standing relationships with private equity buyers and growth funds
• •Personally advising DealFlowAgent founders for the past four years

Emerson Patton

Sector Specialist: Building Services & Facilities Management

• •20+ years advising owners in building services, fire safety, HVAC, plumbing, and construction
• •Guided 200+ companies through growth, profit improvement, and exit planning
• •Builds equity value and operational structure long before a sale
• •Partners with DFA to prepare owners for exit while the advisory team runs the sale

Kaya Kesici

M&A Advisor, Fire Safety, Security & Compliance

• •17 completed M&A transactions over the past six years across UK SME fire safety, security and compliance-led services
• •Sell-side and buy-side experience, buyer research, acquirer mapping, outreach and live process coordination
• •Information request lists, databook prep, IC-style summaries and EV-to-equity bridge work
• •Direct sector exposure across fire protection, security systems, CCTV, access control and intruder alarms

Previously

Ranger Fire & Security · Complete Building Services · Compliance Group

Sam Pouyan

Senior M&A Advisor

• •10 years across buy-side and sell-side M&A
• •Former investment banking analyst
• •Expert in financial modelling and deal structuring

Joe Lewin

Founder, DealFlowAgent

• •22 completed M&A transactions
• •Direct relationships with hundreds of strategic and financial acquirers
• •Previously built a mobility and field services business to 30 staff and 6 UK warehouses, then sold via competitive process with an EY M&A partner
• •Raised £2m in funding; placed 3rd of 1,900 at OnStage (the "Y Combinator of Europe")
• •Full-stack developer of advanced agent systems and second-brain tooling for the M&A process

Tim Armoo

Partner & Chief Marketing Officer

• •Founded Fanbytes, scaled revenues to £10m+, exited at multi-eight-figure valuation
• •Advises on multiple M&A deals, invests in early-stage ventures
• •Built 700,000+ follower community teaching founders to scale and sell
• •Partnered with DealFlowAgent to expand access for founders to buyers

Recruited Per Deal

Sector Expert

Industry-Specific Advisor

For every engagement we add a sector specialist from your industry to the core team: a 15–25 year operator or advisor with direct relationships in your niche. Recruited per deal so you get the right fit, not a generalist.

The bench is growing. Two senior M&A hires confirmed for late July 2026, selected from 200+ applicants out of Goldman Sachs, Deutsche Bank, EY, KPMG and leading boutique M&A firms. See open roles →

Proprietary Technology

The AI layer behind every advisor

Two in-house AI systems work alongside the human bench. They are software, not people, built and supervised by the advisory team.

AI Agent

Sage

AI Deal Concierge

Available 24/7. Monitors every signal in your deal and keeps the advisory team one step ahead. Trained on thousands of M&A transactions.

AI Agent

Sterling

Buy-Side Deal Origination Agent

Engages 13,000+ acquirers to surface live mandates and intent, then feeds your advisors with warm, ranked buyer matches.